Grass

Grass Bio is a synthetic biology company focused on developing "programmable medicines" that can sense and respond to specific cellular environments. By engineering genetic circuits that function like biological logic gates, the company aims to create therapies that activate only in diseased cells, thereby reducing off-target effects and increasing therapeutic efficacy. Founded by pioneers in the field of genomics and synthetic biology from Harvard and the Wyss Institute, Grass Bio is building a platform to address complex diseases through precise, logic-based molecular interventions. The company's technology integrates machine learning with high-throughput biological screening to optimize the performance of these genetic circuits. Grass Bio is currently in the pre-clinical stage, focusing on oncology and rare genetic disorders.